News

Eli Lilly Says Its New Weight-Loss Pill Is Highly Effective

In eagerly awaited results from a new study, the pharmaceutical company Eli Lilly reports that a pill its scientists ...

Eli Lilly Q2 Preview: Can Mounjaro and Zepbound Keep Delivering?

Eli Lilly & Co. reports Q2 2025 results before the U.S. market opens on August 7. Analysts expect revenue of approximately ...

Eli Lilly drops as trial data for oral obesity drug weigh on Q2 results

Eli Lilly (LLY) stock plunges as Phase 3 trial data for the company's oral weight loss drug orforglipron overshadow better ...

Lilly’s GLP-1 pill cuts body weight by 12.4% in trial, lagging Novo’s Wegovy

Eli Lilly said on Thursday that its experimental GLP-1 pill helped patients lose 12.4% of their body weight after 72 weeks in ...
pharmaphorum5m

Lilly weakens as oral weight-loss drug data underwhelms

For comparison, Lilly's arch-rival in the weight-loss category, Novo Nordisk, is developing an oral formulation of GLP-1/amylin agonist amycretin that achieved reductions of between 10.4% and 13.1% in ...

Pill Causes Major Weight Loss in Eli Lilly Trial’s Results

The company said it planned to seek Food and Drug Administration approval for the drug, orforglipron, before the end of the ...

Mounjaro appears more heart protective than Trulicity in trial of Eli Lilly diabetes drugs

Eli Lilly said on Thursday that its newer diabetes drug Mounjaro outperformed Trulicity, its previously top-selling ...

Eli Lilly's Mounjaro shows heart health benefits in head-to-head trial with older diabetes drug Trulicity

Eli Lilly said it believes the new data bolsters the case for Mounjaro to be prescribers’ first choice for patients with Type ...

Eli Lilly beats earnings for second quarter on strong GLP-1 sales, stock dives on GLP-1 pill trial results

Eli Lilly reported second quarter earnings Thursday, a day after competitor Novo Nordisk missed earnings estimates by Wall ...

Wegovy, Mounjaro sales in India double on month in July

Sales of Danish drugmaker Novo Nordisk 's Wegovy and U.S. rival Eli Lilly's Mounjaro in India doubled in July from a month ...

Eli Lilly hikes 2025 outlook, tops quarterly estimates as Mounjaro, Zepbound sales soar

Eli Lilly hiked its 2025 guidance and posted second-quarter earnings that topped estimates on strong demand for its blockbuster weight loss and diabetes drugs.